Exane Derivatives’s Salesforce CRM Stock Holding History

Exane Derivatives’s Portfolio CRM Stock Details CRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1.28M	Sell	7,751 -1,476	-16%	-$261K	0.74%	32
2022 Q1	$1.96M	Buy	9,227 +1,921	+26%	+$413K	0.55%	37
2021 Q4	$1.86M	Sell	7,306 -2,155	-23%	-$606K	0.45%	43
2021 Q3	$2.57M	Buy	9,461 +83	+0.9%	+$21.1K	0.62%	28
2021 Q2	$2.29M	Buy	9,378 +1,327	+16%	+$306K	0.52%	31
2021 Q1	$1.71M	Sell	8,051 -1,084	-12%	-$241K	0.49%	42
2020 Q4	$2.03M	Buy	9,135 +1,533	+20%	+$373K	0.6%	32
2020 Q3	$1.91M	Sell	7,602 -120	-2%	-$26.3K	0.55%	39
2020 Q2	$1.45M	Sell	7,722 -382	-5%	-$64.4K	0.39%	74
2020 Q1	$1.17M	Sell	8,104 -1,910	-19%	-$327K	0.33%	74
2019 Q4	$1.81M	Buy	10,014 +2,108	+27%	+$330K	0.34%	86
2019 Q3	$1.17M	Buy	7,906 +3,553	+82%	+$540K	0.21%	91
2019 Q2	$660K	Buy	4,353 +3,619	+493%	+$567K	0.12%	139
2019 Q1	$116K	Buy	+734	New	+$114K	0.02%	281
2018 Q2	–	Sell	-998	Closed	-$127K	–	687
2018 Q1	$113K	Sell	998 -14,369	-94%	-$1.65M	0.02%	288
2017 Q4	$1.57M	Buy	15,367 +15,220	+10,354%	+$1.55M	0.27%	67
2017 Q3	$13.7K	Sell	147 -831	-85%	-$76.4K	﹤0.01%	379
2017 Q2	$84.7K	Buy	+978	New	+$85.2K	0.02%	286
2017 Q1	–	Sell	-912	Closed	-$62.4K	–	594
2016 Q4	$62.4K	Hold	912	–	–	0.01%	282
2016 Q3	$65K	Hold	912	–	–	0.01%	276
2016 Q2	$72.4K	Sell	912 -303	-25%	-$23.8K	0.01%	259
2016 Q1	$89.7K	Sell	1,215 -417	-26%	-$28.7K	0.01%	253
2015 Q4	$128K	Buy	+1,632	New	+$127K	0.02%	185
2015 Q3	–	Sell	-255	Closed	-$17.8K	–	545
2015 Q2	$17.8K	Sell	255 -2,930	-92%	-$209K	﹤0.01%	346
2015 Q1	$213K	Buy	+3,185	New	+$198K	0.02%	202

Other funds holding CRM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Exane Derivatives's CRM Position: Q2 2022 in Review

Exane Derivatives reduced its Salesforce (CRM) stake by 16% in Q2 2022, selling an estimated $261K and leaving 7,751 shares worth $1.28M. The position accounts for 0.74% of the portfolio, ranked #32.

Exane Derivatives first reported a position in CRM in Q1 2015 and has held it in 25 quarters since. The position peaked at $2.57M in Q3 2021. 2,137 funds tracked by Wall St. Rank hold CRM as of Q2 2022.

Exane Derivatives held 7,751 shares of Salesforce worth $1.28M as of Q2 2022.
Exane Derivatives sold 1,476 Salesforce shares in Q2 2022, an estimated $261K.
Salesforce made up 0.74% of Exane Derivatives's portfolio in Q2 2022, its #32 holding.
Exane Derivatives first reported a position in Salesforce in Q1 2015 and has held it in 25 quarters since.
Exane Derivatives's Salesforce position peaked at $2.57M in Q3 2021.
2,137 funds tracked by Wall St. Rank held Salesforce as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.